Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
Authors
Keywords
-
Journal
Science Advances
Volume 5, Issue 12, Pages eaay1357
Publisher
American Association for the Advancement of Science (AAAS)
Online
2019-12-12
DOI
10.1126/sciadv.aay1357
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted antibody and cytokine cancer immunotherapies through collagen affinity
- (2019) Jun Ishihara et al. Science Translational Medicine
- Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy
- (2019) Noor Momin et al. Science Translational Medicine
- Tumor targeting via EPR: Strategies to enhance patient responses
- (2018) Susanne K. Golombek et al. ADVANCED DRUG DELIVERY REVIEWS
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
- (2018) Young Kwang Chae et al. Journal for ImmunoTherapy of Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events
- (2017) Jun Ishihara et al. Science Translational Medicine
- Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
- (2016) Yuko Nakamura et al. BIOCONJUGATE CHEMISTRY
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
- (2016) Edward W. Roberts et al. CANCER CELL
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix
- (2016) Hui Liang et al. Scientific Reports
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-intrinsic oncogene pathways mediating immune avoidance
- (2015) Stefani Spranger et al. OncoImmunology
- Evaluation of antibody–chemokine fusion proteins for tumor-targeting applications
- (2014) Christian Hess et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting
- (2013) Miriam Merad et al. Annual Review of Immunology
- Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
- (2013) Melissa G. Lechner et al. JOURNAL OF IMMUNOTHERAPY
- Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice
- (2011) Benfan Wang et al. BMC IMMUNOLOGY
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection
- (2011) Mieke Gouwy et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Targeting of drugs and nanoparticles to tumors
- (2010) Erkki Ruoslahti et al. JOURNAL OF CELL BIOLOGY
- Delivery of Therapeutic Proteins
- (2010) Dipak S. Pisal et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Why are tumour blood vessels abnormal and why is it important to know?
- (2009) J A Nagy et al. BRITISH JOURNAL OF CANCER
- The biology of CCR5 and CXCR4
- (2009) Ghalib Alkhatib Current Opinion in HIV and AIDS
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started